End-point variability and smallest effective ISS. by James P. Herman (304807)

“…<p>We define baseline end-point variability (σ_b) as: the standard deviation of primary saccade gain during the final 50 trials of the baseline phase. …”

Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation by Yaowaluk Tariwong (22630109)

Intake and digestibility during two digestibility trials (1: 20–28 d; 2: 50–56 d) of dairy calves fed different additives in the starter feed (n = 15). by Luisa F. L. Salazar (6664121)

Hamster weight as an end-point for leptospiral infection. by Mariana L. Coutinho (337710)

“…</b> Control animals sham-immunized with phosphate-buffered saline (PBS) had stable or increasing weights until day 8 or 9 after challenge, after which they lost weight and met the end-point criterion of a 10% weight decrease (lines represent individual animals).…”

Decreased inflammatory markers of peritoneal macrophages following <i>in vivo</i> treatment with p30A peptide. by Jérôme Rambert (46851)

Concentration of DRS-B2 and [W/F]³-DRS-B2 that inhibits 50% of cell growth (GI₅₀) extracted from Fig 12. by Célia Dos Santos (306471)

The Intracellular level of FLASH decreases during apoptosis. by Song Chen (69646)

Nicotine-induced Tumor Growth is decreased by BEL. by Lindsay E. Calderon (332344)

Piceatannol decreases renal fibrosis in the UUO kidney. by Sin Young Choi (3370778)

T198A/G substitution markedly decrease p27 protein stability. by Monica Schiappacassi (227672)

PV1-treated mice exhibited a decrease in overall activation of T lymphocytes. by Pedro Henrique Papotto (791904)

Galiellalactone decreases the proportion of ALDH+ prostate cancer cells in vitro and the ALDH1A1 expression in vivo. by Rebecka Hellsten (348459)

“…<p>A. DU145 and LNCaP-IL6 cells were treated with galiellalactone (5–50 µM) for 24 h and subjected to ALDEFLUOR® assay. …”

NatB-inactivation decreased Drk levels through its N-terminal sequences, which was regulated by the N-end rule E3 ubiquitin ligase POE/UBR4. by Zhentao Sheng (107495)

Overexpression of PLIC-1 decreased Trif abundance in a Nocodazole-sensitive manner. by Nabanita Biswas (349647)

<i>btuE</i> expression results in decreased intracellular ROS. by Felipe A. Arenas (23050)

Longitudinal associations between baseline CVR and 2 years changes in BDI-II score in participants with a BDI-II score <18 in the PREDIMED-PLUS trial at baseline. by Sandra Martín-Peláez (11353470)

Subjects:

Association between cardiovascular risk and a) depressive status (BDI-II ≥18) and b) BDI-II score, in the PREDIMED-PLUS trial, stratified by CVR factors, at baseline. by Sandra Martín-Peláez (11353470)

Subjects:

Proportion of CD25⁺CD16^low cells among CD3^-CD11b⁺ cells according to the dose of anti-thymocyte globulin. by Youngmin Ko (3333819)

Subjects:

Baseline and end-point pain scores in the pregabalin and placebo groups, 2003–2020. by Emma T. L. Cheng (14486376)

Subjects:

Antitumor Activity of FGFR Inhibitor as a Result of a Decrease in the Breast TIC Subpopulation In Vivo. by Sungeun Kim (105743)